Colorado's Cannabis Sales for 2017 Reach $1.6 Billion | CashCropToday
0 Shares 160 Views

Colorado’s Cannabis Sales for 2017 Reach $1.6 Billion

February 13, 2018
160 Views

Colorado retailed $1.5 billion dollars’ worth of medical and recreational cannabis last year,  up 15% from 2016. Although recent over supply in the states market has caused to price per gram to drop significantly, demand is still stronger than ever.

Colorado was the first state in the U.S. to legalized cannabis for recreational consumption back in 2014. Taxes from the sale of cannabis has grown exponentially every year and in 2017 the state generated over $200 million dollars in taxes alone.

Total revenue from cannabis taxes, licenses, and fee revenue:

Calendar Year Total Revenue
2014 $67,594,323
2015 $130,411,173
2016 $193,604,810
2017 $247,368,473
2018 (Jan) $21,681,438

 

Cannabis legalization has had other positive effects on the state. According to new research by the American Journal of Public Health, the legalization of cannabis has caused opioid related deaths and overdoses to drop state wide by 6%. Actually, Denver’s violent crime rate dropped 2%, as well as, an 8% drop in property related crimes. It’s clear that Colorado’s experiment has now set a precedence for other states considering legalization.

Sources:
Colorado Department of Revenue
Marijuana Business Daily
The Washington Post

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
274 views
Market Watch
274 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
195 views
Global
195 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
191 views
Manufacturing
191 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: